OTC · NWPN
The Now Corporation
$0.02+$0.00 (+22.67%)
The Now Corporation’s quoted price sits in the lower half of its reported 52-week range, 87.73% below the high.
Loading market information…
OTC · NPHC · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nutra Pharma Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nutra Pharma Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nutra Pharma Corp. (NPHC) operates as a biopharmaceutical firm specializing in obtaining, licensing, and bringing to market a variety of pharmaceutical products, cutting-edge technologies, and both homeopathic and ethical medications. The company primarily targets the U.S. market, focusing its efforts on managing conditions such as pain, neurological ailments, cancer, autoimmune diseases, and infectious diseases. Its current commercial offerings include: Nyloxin and Nyloxin Extra Strength: These products are distributed as an oral spray for alleviating lower back pain, migraines, neck and shoulder discomfort, cramps, and neuropathic pain, and as a topical gel to relieve joint pain, arthritis, and repetitive stress injuries. Pet Pain-Away: An over-the-counter (OTC) homeopathic, non-narcotic, and non-addictive solution for chronic pain in household pets. Luxury Feet: An OTC pain reliever and anti-inflammatory designed to ease foot pain or discomfort specifically caused by high heels and stilettos. Nyloxin Military Strength: A specialized formulation for pain relief aimed at the United States Military and Veteran's Administration. Equine Pain-Away: An OTC topical pain management product for horses. Beyond its existing portfolio, Nutra Pharma Corp. is also advancing several pipeline candidates: RPI-78M: In development to treat neurological conditions such as multiple sclerosis, adrenomyeloneuropathy, and amyotrophic lateral sclerosis, alongside autoimmune diseases like rheumatoid arthritis and myasthenia gravis. RPI-MN: Under investigation for viral diseases, including human immunodeficiency virus (HIV/AIDS) and herpes, as well as for general antiviral applications. RPI-78: Being developed for applications in pain and arthritis. RPI-70: Also in development for pain relief. Founded in 2000, the company is headquartered in Plantation, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.02+$0.00 (+22.67%)
The Now Corporation’s quoted price sits in the lower half of its reported 52-week range, 87.73% below the high.
$0.00+$0.00 (+14.94%)
China Infrastructure Construction Corp.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.01$0.00 (0.0%)
Cann American Corp.’s quoted price sits in the upper half of its reported 52-week range, 43.88% below the high.
$0.00$0.00 (0.0%)
Dakshidin Corporation’s quoted price sits in the lower half of its reported 52-week range, 57.14% below the high.
$0.00+$0.00 (+100.0%)
Herborium Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
EVIO, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Rimrock Gold Corp.’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
$0.00$0.00 (0.0%)
Nutranomics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
